ERBB2 and neoplasm: The expression of DJ-1 was significantly higher in HR+ subtypes patients tumor samples compared to normal counterparts but not in HER2+ or triple-negative breast cancer (TNBC, HR−, and HER2−) subtypes (Figure 2(b)).